Literature DB >> 23295225

S-nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity.

Tereza Hartmanová1, Vojtěch Tambor, Juraj Lenčo, Claudia A Staab-Weijnitz, Edmund Maser, Vladimír Wsól.   

Abstract

Carbonyl reductase 1 (CBR1 or SDR21C1) is a ubiquitously-expressed, cytosolic, monomeric, and NADPH-dependent enzyme. CBR1 participates in apoptosis, carcinogenesis and drug resistance, and has a protective role in oxidative stress, cancer and neurodegeneration. S-Nitrosoglutathione (GSNO) represents the newest addition to its diverse substrate spectrum, which includes a wide range of xenobiotics and endogenous substances. GSNO has also been shown to covalently modify and inhibit CBR1. The aim of the present study was to quantify and characterize the resulting modifications. Of five candidate cysteines for modification by 2 mM GSNO (positions 26, 122, 150, 226, 227), the last four were analyzed using MALDI-TOF/TOF mass spectrometry and then quantified using the Selected Reaction Monitoring Approach on hyphenated HPLC with a triple quadrupole mass spectrometer. The analysis confirmed GSNO concentration-dependent S-glutathionylation of cysteines at positions 122, 150, 226, 227 which was 2-700 times higher compared to wild-type CBR1 (WT-CBR1). Moreover, a disulfide bond between neighboring Cys-226 and Cys-227 was detected. We suggest a role of these two cysteines as a redox-sensitive cysteine pair. The catalytic properties of wild-type and enzyme modified with 2 mM GSNO were also investigated by steady state kinetic experiments with various substrates. GSNO treatment of CBR1 resulted in a 2-5-fold decrease in kcat with menadione, 4-benzoylpyridine, 2,3-hexanedione, daunorubicin and 1,4-naphthoquinone. In contrast, the same treatment increased kcat for substrates containing a 1,2-diketo group in a ring structure (1,2-naphthoquinone, 9,10-phenanthrenequinone, isatin). Except for 9,10-phenanthrenequinone, all changes in kcat were at least in part compensated for by a similar change in Km, overall yielding no drastic changes in catalytic efficiency. The findings indicate that GSNO-induced covalent modification of cysteine residues affects the kinetic mechanism of CBR1 both in terms of substrate binding and turnover rate, probably by covalent modification of Cys-226 and/or Cys-227.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295225     DOI: 10.1016/j.cbi.2012.12.011

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  5 in total

1.  CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.

Authors:  Adolfo Quiñones-Lombraña; Nasi Li; Virginia Del Solar; G Ekin Atilla-Gokcumen; Javier G Blanco
Journal:  Biopharm Drug Dispos       Date:  2018-06       Impact factor: 1.627

Review 2.  Protein S-Nitrosylation: Determinants of Specificity and Enzymatic Regulation of S-Nitrosothiol-Based Signaling.

Authors:  Colin T Stomberski; Douglas T Hess; Jonathan S Stamler
Journal:  Antioxid Redox Signal       Date:  2018-01-10       Impact factor: 8.401

3.  Upregulation of capacity for glutathione synthesis in response to amino acid deprivation: regulation of glutamate-cysteine ligase subunits.

Authors:  Angelos K Sikalidis; Kevin M Mazor; Jeong-In Lee; Heather B Roman; Lawrence L Hirschberger; Martha H Stipanuk
Journal:  Amino Acids       Date:  2014-02-21       Impact factor: 3.520

4.  Pleiotropic functions of glutathione S-transferase P.

Authors:  Jie Zhang; Christina Grek; Zhi-Wei Ye; Yefim Manevich; Kenneth D Tew; Danyelle M Townsend
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

5.  Overexpression of Catalase Diminishes Oxidative Cysteine Modifications of Cardiac Proteins.

Authors:  Chunxiang Yao; Jessica B Behring; Di Shao; Aaron L Sverdlov; Stephen A Whelan; Aly Elezaby; Xiaoyan Yin; Deborah A Siwik; Francesca Seta; Catherine E Costello; Richard A Cohen; Reiko Matsui; Wilson S Colucci; Mark E McComb; Markus M Bachschmid
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.